Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...
Among patients with mycosis fungoides (MF) and Sézary syndrome (SS), the T-cell receptor (TCR) clonal Vb20 segment was significantly associated with advanced-stage disease, folliculotropism with ...
Spicy food makes us sweat because capsaicin, the active compound in chili peppers, tricks the body’s heat sensors into ...
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...
GAITHERSBURG, Md., US, November 6, 2025) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore” or the "Company”), a commercial-stage biotechnology company pioneering and delivering transformative ...
If you're a new investor and tend to gravitate toward growth stocks, there are plenty of compelling buys to consider in the ...
(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...
LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV):Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2 ...
Today, GoLocker, New York City's dedicated distribution and access point provider announced a partnership with Toys for Hospitalized Children (TFHC) to transform its network of neighborhood lockers ...
Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback